Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Clene Nanomedicine has raised $4.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
Clene Nanomedicine's investors include Vivo Capital, National Institutes of Health, Coastlands Capital, National Multiple Sclerosis Society (NMSS), Kensington Capital Holdings.
Clene Nanomedicine is headquartered in Salt Lake City, United States.
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Clene Nanomedicine is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Clene Nanomedicine — Funding & Investors." VCBacked, September 15, 2026, https://www.vcbacked.co/company/clene-nanomedicine. Accessed October 16, 2026.
VCBacked. (2026). Clene Nanomedicine — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/clene-nanomedicine
{{cite web |title=Clene Nanomedicine — Funding & Investors |url=https://www.vcbacked.co/company/clene-nanomedicine |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated